Paraplegia News and Research

RSS

Paraplegia is an impairment in motor or sensory function of the lower extremities. It is usually the result of spinal cord injury or a congenital condition such as spina bifida which affects the neural elements of the spinal canal.

Neuralstem commences dosing in NSI-189 Phase Ib trial for major depressive disorder

Neuralstem, Inc. announced that the first patients were dosed in Phase Ib of its ongoing trial to test the safety of NSI-189 in the treatment of major depressive disorder (MDD).

25 Jun 2012

Stem Cells reports results of Neuralstem ALS Phase I trial

Neuralstem, Inc. announced that safety results from the first 12 patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) to receive its stem cells were reported online in the peer-reviewed publication, Stem Cells, on March 13th.

29 Mar 2012

Ekso Bionics, Kessler Foundation partner to test commercial robotic exoskeleton

On Monday, Kessler Foundation became the second rehabilitation research center in the U.S. to implement Ekso, a wearable, robotic battery-powered exoskeleton that allows wheelchair users with lower-extremity weakness to stand and walk.

2 Mar 2012

Intraoperative monitoring of spinal cord may help prevent paralysis

The American Academy of Neurology is issuing an updated guideline that recommends monitoring the spinal cord during spinal surgery and certain chest surgeries to help prevent paralysis, or loss of muscle function, related to the surgeries.

21 Feb 2012

Neuralstem announces registered direct placement of 5,200,000 shares of common stock

Neuralstem, Inc. announced today that it has entered into agreements with certain institutional and accredited investors for a registered direct placement of 5,200,000 shares of common stock at a price of $1.00 per share for aggregate gross proceeds of $5,200,000.

6 Feb 2012

Kessler scientists monitor Ekso device in six patients with traumatic SCI

Monitored by scientists at Kessler Foundation, six people with traumatic spinal cord injuries tested Ekso, the robotic exoskeleton from Ekso Bionics that enables wheelchair users to stand and walk.

16 Dec 2011

Neuralstem initiates spinal cord neural stem cell trial in ALS

Neuralstem, Inc. announced that the first patient to receive stem cells in the cervical (upper back) region of the spine was treated on Friday in its ongoing trial to test the safety of its spinal cord neural stem cells in amyotrophic lateral sclerosis.

23 Nov 2011

FDA approves intraspinal injections in spinal cord stem cell ALS trial

Neuralstem, Inc. updated the progress of its ongoing Phase I safety trial of the company's spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) at Emory University in Atlanta, Georgia.

24 Oct 2011

Researchers identify unusual genomic architecture linked with very severe forms of disease

When cells divide normally, DNA gets copied perfectly and distributed among the daughter cells with an even hand. Occasionally though, DNA breaks during division and is rearranged, resulting in duplications or deletions of important parts of the blueprint.

3 Oct 2011

DryDiapersPlus joins Unique Wellness and BIOTX to provide incontinence products

DryDiapersPlus is excited to announce that they have joined with Unique Wellness and BIOTX Ltd to provide world-class incontinence products for their customers.

16 Sep 2011

Simvastatin may reduce spinal cord damage from ischemia/reperfusion injury

The cholesterol-lowering drug simvastatin appears to reduce spinal cord injury caused by oxygen deprivation in experimental animals, according to a study in the September issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

24 Aug 2011

Neuralstem receives U.S. patent allowance for three new neurogenic compounds

Neuralstem, Inc. announced that it has received notice of allowance for U.S. Patent Applications 12/939,897 and 12/939,914 entitled: "Compositions to Effect Neuronal Growth."

15 Jul 2011

Scientists probe 'atlastin,' a protein linked to hereditary spastic paraplegia

New research from Rice University and Italy's Eugenio Medea Scientific Institute is yielding clues about hereditary spastic paraplegia (HSP), a group of inherited neurological disorders that affect about 20,000 people in the United States.

11 Jul 2011

SPI and Neuralstem sign licensing agreement for major depression drug, NSI-189

Neuralstem, Inc. announced that it has signed an exclusive agency licensing agreement with Summit Pharmaceuticals International Corporation, of Tokyo, Japan (SPI), a wholly owned subsidiary of Sumitomo Corporation Group.

8 Jun 2011

Relay stent-graft safe and effective for patients with aortic dissections

Aortic dissection is rare, but when it occurs, a patient's prognosis can be poor, even with timely medical diagnosis and treatment. It is the most frequently diagnosed lethal condition of the aorta.

12 May 2011

Neuralstem signs MoU with BaYi Brain Hospital for ischemic stroke program in China

Neuralstem, Inc. (NYSE Amex: CUR) announced it has signed a Memorandum of Understanding with BaYi Brain Hospital in Beijing, China.

21 Apr 2011

Neuralstem to present HSSC Phase I trial data in amyotrophic lateral sclerosis at AAN meeting

Neuralstem, Inc. announced that the Phase I safety trial of its human spinal cord stem cells in amyotrophic lateral sclerosis is the subject of three presentations at the American Academy of Neurology Annual Meeting, April 9-16th, in Honolulu, HI.

7 Apr 2011

Researchers investigate why immune system is blunted after spinal cord injury

Mobility is a challenge for spinal cord injured patients. Infection is another. Adam Thrasher, assistant professor of health and human performance, says infection is the leading cause of death for people living with spinal cord injuries for two years or more.

4 Mar 2011

Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder

Neuralstem, Inc. announced that the first subject was dosed yesterday in a Phase Ia trial to evaluate the safety of its drug, NSI-189, which is being developed for the treatment of major depressive disorder and other psychiatric indications. NSI-189 is the lead compound in Neuralstem's neurogenerative small molecule drug platform. This phase of the trial is in healthy volunteers and seeks to determine the maximum tolerated single dose.

2 Mar 2011

$Tip sheets provide details on hip and knee fracture treatment$

Tip sheets provide details on hip and knee fracture treatment

Patients who wait more than 36 hours for surgery to correct a hip fracture have a 39 percent rate of medical complication and those who wait 48 hours have a 46 percent complication rate. Patients who receive surgical treatment within 24 hours have a lower complication rate of 25 percent and a shorter hospital stay. Each day the surgery was delayed added an additional two days to hospital stay.

21 Feb 2011